Cardiovascular Pharmacology of Estradiol Metabolites
- 1 December 2003
- journal article
- review article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 308 (2), 403-409
- https://doi.org/10.1124/jpet.103.058057
Abstract
A discussion of the role of endogenous estradiol metabolites in mediating important biological actions of estradiol is essentially nonexistent in standard textbooks of pharmacology and endocrinology. Indeed, the prevailing view is that all biological effects of estradiol are initiated by binding of estradiol per se to estrogen receptors and that estradiol metabolites are more or less irrelevant. This orthodox view, which is most likely incorrect, is the fundamental premise (an estrogen is an estrogen is an estrogen) underlying the design of important clinical trials such as the Heart and Estrogen/Progestin Replacement Study and the Women's Health Initiative Study. Accumulating data provide convincing evidence that some metabolites of estradiol, the major estrogen secreted by human ovaries, are biologically active and mediate multiple effects on the cardiovascular and renal systems that are largely independent of estrogen receptors. More specifically, metabolites of estradiol, particularly catecholestradiols and methoxyestradiols, induce multiple estrogen receptor-independent actions that protect the heart, blood vessels, and kidneys from disease. These protective effects are mediated in part by the inhibition of the ability of vascular smooth muscle cells, cardiac fibroblasts, and glomerular mesangial cells to migrate, proliferate, and secrete extracellular matrix proteins, as well as by an improvement in vascular endothelial cell function. The purpose of this review is to highlight the cardiovascular and renal pharmacology of catecholestradiols and methoxyestradiols. The take home message is simple: that when it comes to cardiovascular and renal protection, the concept that all estrogenic compounds are created equal may not be true.Keywords
This publication has 37 references indexed in Scilit:
- CYP450- and COMT-Derived Estradiol Metabolites Inhibit Activity of Human Coronary Artery SMCsHypertension, 2003
- Methoxyestradiols mediate estradiol-induced antimitogenesis in human aortic SMCs.Hypertension, 2002
- Methoxyestradiols Mediate the Antimitogenic Effects of Locally Applied Estradiol on Cardiac Fibroblast GrowthHypertension, 2002
- Role of methoxyestradiols in the growth inhibitory effects of estradiol on human glomerular mesangial cells.Hypertension, 2002
- Invited Review: Cardiovascular protective effects of 17β-estradiol metabolitesJournal of Applied Physiology, 2001
- Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanismsAmerican Journal of Physiology-Renal Physiology, 2001
- Methoxyestradiols Mediate the Antimitogenic Effects of Estradiol on Vascular Smooth Muscle Cells via Estrogen Receptor-Independent MechanismsBiochemical and Biophysical Research Communications, 2000
- Estrogen-Induced Vasoprotection Is Estrogen Receptor DependentCirculation, 2000
- 17β-Estradiol, Its Metabolites, and Progesterone Inhibit Cardiac Fibroblast GrowthHypertension, 1998
- 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site.Proceedings of the National Academy of Sciences of the United States of America, 1994